Humacyte (HUMA) Non Operating Income (2020 - 2026)

Humacyte (HUMA) has reported Non Operating Income for 7 consecutive years, with -$9.8 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Non Operating Income fell 23.64% year-over-year to -$9.8 million in Q2 2026; TTM through Jun 2026 was $14.4 million, a 72.57% decrease from a year earlier, with the FY2025 full-year figure at $67.3 million, up 296.2% from the prior year.
• Non Operating Income was -$9.8 million for Q2 2026 at Humacyte, down from $11.3 million in the prior quarter.
• Over five years, Non Operating Income peaked at $62.3 million in Q1 2025 and troughed at -$27.2 million in Q2 2024.
• A 5-year average of $5.4 million and a median of $1.5 million in 2022 frame the typical range for Non Operating Income.
• Across the five-year window, Non Operating Income soared 2574.99% in 2022 and sank 848.68% in 2023, its largest moves.
• Over 5 years, Non Operating Income stood at $17.1 million in 2022, then plunged by 93.7% to $1.1 million in 2023, then soared by 564.31% to $7.1 million in 2024, then retreated by 15.61% to $6.0 million in 2025, then slumped by 262.57% to -$9.8 million in 2026.
• The last three Non Operating Income figures came in at -$9.8 million (Q2 2026), $11.3 million (Q1 2026), and $6.0 million (Q4 2025), per Business Quant data.